Technical Analysis for BPMC - Blueprint Medicines Corporation

Grade Last Price % Change Price Change
grade B 90.29 -1.53% -1.40
BPMC closed down 1.53 percent on Wednesday, June 26, 2019, on 69 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical BPMC trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.53%
Calm After Storm Range Contraction -1.53%
Multiple of Ten Bullish Other -1.53%
Wide Bands Range Expansion -1.53%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.73%
Outside Day Range Expansion -2.73%

Older signals for BPMC ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company's lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4. It is also developing a drug candidate to target RET, a receptor tyrosine kinase that can becomes abnormally activated when a portion of the gene that encodes RET is joined to part of another gene; and RET resistant mutants that would arise from treatment with first generation therapies, as well as a program that targets rare genetic diseases. The company has a research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is based in Cambridge, Massachusetts.
Biopharmaceutical Cancer Cell Biology Cell Signaling Tyrosine Kinase Receptors Protein Kinase Inhibitor Mastocytosis Tyrosine Kinase Gastrointestinal Stromal Tumor Myeloproliferative Neoplasm Rare Genetic Disease Rare Genetic Diseases Systemic Mastocytosis
Is BPMC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 100.76
52 Week Low 44.58
Average Volume 482,886
200-Day Moving Average 72.2934
50-Day Moving Average 82.2168
20-Day Moving Average 88.1115
10-Day Moving Average 93.55
Average True Range 4.2823
ADX 17.77
+DI 30.324
-DI 22.9333
Chandelier Exit (Long, 3 ATRs ) 87.9131
Chandelier Exit (Short, 3 ATRs ) 80.05689999999999
Upper Bollinger Band 101.8902
Lower Bollinger Band 74.3328
Percent B (%b) 0.58
BandWidth 31.2756
MACD Line 3.3936
MACD Signal Line 3.4833
MACD Histogram -0.0897
Fundamentals Value
Market Cap 3.53 Billion
Num Shares 39.1 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -28.94
Price-to-Sales 103.31
Price-to-Book 7.06
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 95.72
Resistance 3 (R3) 96.18 94.83 94.82
Resistance 2 (R2) 94.83 93.45 94.60 94.51
Resistance 1 (R1) 92.56 92.59 91.89 92.10 94.21
Pivot Point 91.21 91.21 90.87 90.98 91.21
Support 1 (S1) 88.94 89.83 88.27 88.48 86.37
Support 2 (S2) 87.59 88.97 87.36 86.07
Support 3 (S3) 85.32 87.59 85.77
Support 4 (S4) 84.86